Adial Pharmaceuticals, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Cary John Claiborne
- Full Time Employees
- 5
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1180 Seminole Trail Charlottesville VA United States of America 22901
- IPO Date
- Jul 27, 2018
- CIK
- 0001513525
- Website
- adialpharma.com
- Similar Companies
- Business
- Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of genetically targeted therapies for addiction and related disorders. The company's primary product is AD04, a serotonin-3 receptor antagonist in Phase 3 clinical trials, designed for the treatment of Alcohol Use Disorder (AUD) in patients with specific genetic markers identified through a proprietary companion diagnostic genetic test. AD04 aims to reduce heavy drinking and improve patient outcomes, with potential applications also being explored for opioid use disorder, gambling, and obesity. The company operates primarily in the United States with plans for broader commercialization. Adial Pharmaceuticals manufactures AD04 tablets through partnerships with U.S.-based contract manufacturers including Thermo Fisher Scientific, Cambrex, and Tedor Pharma to secure drug substance and drug product supply suitable for clinical development and commercialization. The company also offers a proprietary genetic testing solution through its collaboration with Genomind, facilitating patient identification for targeted therapy. Recent major developments include successful completion of the End of Phase 2 meeting with the FDA in 2025, which endorsed the company's adaptive Phase 3 trial design for AD04 as a genetically targeted therapy for AUD. The FDA validated the 505(b)(2) regulatory pathway and recognized the company's proprietary companion diagnostic as a Non-Significant Risk for use in clinical trials. Additionally, Adial secured approximately $2.86 million through a warrant inducement transaction to support its clinical and operational activities. The company filed an updated provisional patent protecting AD04's use in genetically defined patient populations with intellectual property protection extended potentially through 2045. It also received a 180-day Nasdaq compliance extension while strategically positioning itself for partnerships with larger pharmaceutical firms to leverage commercial infrastructure. Founded in 2004 and headquartered in Glen Allen, Virginia, Adial Pharmaceuticals is focused on advancing its addiction treatment pipeline through genetic precision medicine approaches. Its current development portfolio includes AD04 for AUD and an adenosine platform targeting non-opioid pain treatments and cocaine addiction. The company targets specialist markets and aims to expand into U.S. primary care and European commercial markets as it progresses toward commercialization. Adial’s strategic focus on biomarker-driven therapy development, coupled with recent manufacturing agreements and patent enhancements, positions it as an innovator in addiction therapeutics with a compelling late-stage clinical asset in AD04 and a growing intellectual property portfolio. The company continues to actively seek strategic alliances to further its clinical programs and commercial reach.
Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update
Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045
Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program
Adial Pharmaceuticals Submits Application to FDA Commissioner's National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Down 49.4% in April
Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Up 21.7% in March
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Sees Large Drop in Short Interest
Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement
Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One
Contrasting Kaleido Biosciences (NASDAQ:KLDO) and Adial Pharmaceuticals (NASDAQ:ADIL)
Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04
Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement
Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Decreases By 31.2%
Adial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Drops By 59.6%
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Sees Large Decline in Short Interest
Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show
Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution
Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04